March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate ...

Altimmune's stock, which was added to the Nasdaq Biotechnology Index (NBI) in December, has a short interest of 28.2%, ...

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares. AI is about to change ...

Meeting to be held in Boston on April 9 and in New York on April 10 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

In the last three months, 8 analysts have published ratings on Altimmune (NASDAQ:ALT), offering a diverse range of perspectives from bullish to bearish. The table below provides a concise overview ...

Real time quote data is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

Altimmune has a huge opportunity with its promising GLP-1 drug. Moderna isn't just a pandemic stock. Pfizer is trading at a ridiculously cheap valuation and pays a juicy dividend. David Jagielski ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies, has been garnering significant attention from analysts and ...